ARRIVENT BIOPHARMA, INC. Payments to Acquire Investments
ARRIVENT BIOPHARMA, INC. (AVBP) reported Payments to Acquire Investments of $78.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. payments to acquire investments for the quarter ending 2026-06-30 was $13.99M, a 35.12% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. payments to acquire investments for the quarter ending 2026-03-31 was $64.38M, a 555.83% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. payments to acquire investments for the quarter ending 2025-12-31 was $151.18M.
- ARRIVENT BIOPHARMA, INC. payments to acquire investments for the quarter ending 2025-09-30 was $90.37M.
- ARRIVENT BIOPHARMA, INC. payments to acquire investments for fiscal 2025 was $272.93M, a 40.57% increase from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. payments to acquire investments for fiscal 2024 was $194.16M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $78.38M 10-Q · filed 2026-08-12 | $229.56M derived: sum of 3 quarters · filed 2026-08-12 | $319.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $64.38M 10-Q · filed 2026-05-11 | $215.56M derived: sum of 2 quarters · filed 2026-05-11 | $305.93M derived: sum of 3 quarters · filed 2026-05-11 | $327.50M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $151.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $241.55M derived: sum of 2 quarters · filed 2026-03-05 | $263.12M derived: sum of 3 quarters · filed 2026-08-12 | $272.93M 10-K · filed 2026-03-05 |
| 2025-09-30 | $90.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $111.94M derived: sum of 2 quarters · filed 2026-08-12 | $121.75M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $21.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $31.39M 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $9.82M 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | $194.16M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |